Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paeoniflorin for Autoimmune Hepatitis
NCT02878863Phase 3Withdrawn
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paeoniflorin in autoimmune hepatitis (AIH) (2 arms). Primary endpoint: Percent of patients that achieve biochemical remission of AIH at Month 6. Planned start Aug 2016; status: withdrawn.
02
Drugs
paeoniflorin
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT02878863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878863.